Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06182865
Other study ID # INER-V09DX-proton
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 20, 2023
Est. completion date December 30, 2024

Study information

Verified date December 2023
Source National Atomic Research Institute, Taiwan
Contact Mei-Hui Wang, PhD
Phone +886-3-4711400
Email mhwang@nari.org.tw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-center, prospective, open-labeled, single-arm, interventional study to evaluate liver reserve and tumor response using Ga-68 Dolacga positron emission tomography and the safety of the investigational product in patients with hepatocellular carcinoma before and after proton therapy.


Description:

This is a single-center, prospective, open-labeled, single-arm, interventional study to evaluate liver reserve and tumor response using Ga-68 Dolacga positron emission tomography and the safety of the investigational product in patients with hepatocellular carcinoma before and after proton therapy. This trial will enroll 10 eligible subjects. All subjects will provide informed consent before any study procedures are performed. Screening procedures (visit 1) will occur within 21 days prior to imaging visit (visit 2) and will include: inclusion/exclusion criteria check, pregnancy test (if applicable), vital signs, laboratory tests, electrocardiogram (ECG) and establishment of baseline characteristics. Primovist MRI will occur within 14 days prior to imaging visit (visit 2) and 1 week after imaging visit (visit 4), and will be performed according to standard procedure of study site. The baseline characteristics include medical/medication history, fibrosis index, Child-Pugh score and classification, MELD score, liver oncology diagnosis, tumor size, preoperative treatments (portal vein embolization, transarterial chemoembolization, transarterial embolization or biliary drainage), existence of thrombosis (portal vein thrombosis or hepatic vein thrombosis). The liver tissue fibrosis index FIB-4 will be measured to assess the morphological changes. During the imaging session (visit 2, Day 1; visit 4, Day 84±3), a catheter will be placed for intravenous (IV) administration of Ga-68 Dolacga. Subjects will receive an iv bolus injection of 2.0±1.0 mCi Ga-68 Dolacga. A PET/CT scan will be kinetically performed for 60 minutes immediately after IV injection. The measurement of liver reserve is the primary endpoints of this study and measurement will be evaluated by Ga-68 Dolacga PET. The measurement of liver reserve will be performed at visit 2 and visit 4 of this study for all subjects. Adverse events will be continuously monitored during the imaging session. Two follow-up visits (visit 3 at Day 7±2 and visit 5 at Day 91±2) will be conducted to confirm subject well-being and to collect information about any new adverse events (if any).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10
Est. completion date December 30, 2024
Est. primary completion date December 30, 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria: - Diagnosed with hepatocellular carcinoma and scheduled to have the PBT. - 20~80 years old - Performance status: ECOG 0-1 - Child-Pugh class A Exclusion Criteria: - Massive or uncontrolled ascites - Concurrent with other malignancy - Under pregnancy or breastfeeding - With distant metastasis - Allergic to investigational drug(s) or similar drug(s)/ formulation(s); - Known hypersensitivity to PRIMOVIST - Acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m^2) - General PET and MRI exclusion criteria - Can't follow our follow-up schedule because of any reason

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ga-68 Dolacga Injection
Ga-68 Dolacga will be administered via iv bolus injection followed by a whole-body PET/CT scan for liver reserve evaluation.

Locations

Country Name City State
Taiwan Linkon Chang Gung Memorial Hospital Taoyuan city

Sponsors (1)

Lead Sponsor Collaborator
National Atomic Research Institute, Taiwan

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of liver reserve obtained from the Ga-68 Dolacga PET performed in HCC patients before proton therapy. The liver reserve parameters obtained from Ga-68 Dolacga PET is expressed in "percentage of injection dose (%ID) and standard uptake value, (SUV)." Visit 2 (Day 1)
Primary Measurement of liver reserve obtained from the Ga-68 Dolacga PET performed in HCC patients after proton therapy. The liver reserve parameters obtained from Ga-68 Dolacga PET is expressed in "percentage of injection dose (%ID) and standard uptake value, (SUV)." Visit 4 (Day 84±3)
Secondary Number of subjects with clinically significant changes in systolic blood pressure and diastolic blood pressure from pre-dose to visit 2 (Day 1), visit 3 (Day 7±2), visit 4 (84±3), and visit 5 (Day 91±2)
Secondary Number of subjects with body temperature abnormalities from pre-dose to visit 2 (Day 1), visit 3 (Day 7±2), visit 4 (84±3), and visit 5 (Day 91±2)
Secondary Number of subjects with clinically significant changes in Heart Rate from pre-dose to visit 2 (Day 1), visit 3 (Day 7±2), visit 4 (84±3), and visit 5 (Day 91±2)
Secondary Number of subjects reporting clinically significant changes in serum biochemical tests from pre-dose to visit 2 (Day 1), visit 3 (Day 7±2), visit 4 (84±3), and visit 5 (Day 91±2)
Secondary Number of subjects reporting clinically significant changes in hematological tests from pre-dose to visit 2 (Day 1), visit 3 (Day 7±2), visit 4 (84±3), and visit 5 (Day 91±2)
Secondary Number of subjects reporting clinically significant changes in urinalysis from pre-dose to visit 2 (Day 1), visit 3 (Day 7±2), visit 4 (84±3), and visit 5 (Day 91±2)
Secondary Number of subjects with clinically significant changes in electrocardiogram(ECG) from pre-dose to visit 2 (Day 1), visit 3 (Day 7±2), visit 4 (84±3), and visit 5 (Day 91±2)
Secondary Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) All laboratory abnormalities which are compared with screening values and out of the reference range will be considered as AE and will be assessed its relationship to the study drug. Any ECG changes including ECG waveform will be assessed as AE(s) and will be followed to assess whether they resolved and when they resolved. 91 days
See also
  Status Clinical Trial Phase
Recruiting NCT03253250 - The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection Phase 4
Terminated NCT01760616 - Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy Phase 4
Active, not recruiting NCT04682847 - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Not yet recruiting NCT03149523 - Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors N/A
Recruiting NCT05009550 - ESP Block on Patient Outcomes in Patients With Liver Tumor Undergoing Radiofrequency Ablation N/A
Recruiting NCT06342414 - An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
Recruiting NCT03132740 - Impact of Three-dimensional Visualization on Operation Strategy and Complications for Complex Hepatic Carcinoma
Completed NCT03164382 - Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma Phase 3
Completed NCT03572582 - Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma Phase 2
Completed NCT04266548 - Arterial Base Fluorescence Segmental Positive Staining N/A
Recruiting NCT03013712 - A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer Phase 1/Phase 2
Recruiting NCT01350726 - Functional-three-dimensional Reconstruction of Liver by 99MTc-GSA-SPECT Scan N/A
Completed NCT06245798 - Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
Recruiting NCT06311396 - Development of a Neuronal Microscope N/A
Recruiting NCT04220944 - Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. Phase 1
Completed NCT02332551 - Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder N/A
Completed NCT02352935 - Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function N/A
Completed NCT02834780 - Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma Phase 1
Completed NCT05007548 - to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve Phase 2
Completed NCT03163186 - Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial). N/A